GSK Pharma is expected to post a growth of 1.5% in sales to Rs. 662cr during 2QCY2013. Its OPM is expected to come in at 25.6%, a dip of 550bps, leading to a 15.0% dip in the net profit which is likely to come in at Rs. 144.3cr. We maintain our neutral on the stock.
